Sort   by:  
 Page size 
UnknownApalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Not available
S-EPMC6927320 | biostudies-literature
UnknownA Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Not available
S-EPMC10902357 | biostudies-literature
UnknownPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Not available
S-EPMC2810983 | biostudies-literature
UnknownDuvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Not available
S-EPMC8260004 | biostudies-literature
UnknownSingle-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Not available
S-EPMC5921964 | biostudies-literature
UnknownDuvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Not available
S-EPMC6033052 | biostudies-literature
UnknownPhase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Not available
S-EPMC4840931 | biostudies-literature
UnknownRandomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
Not available
S-EPMC7145586 | biostudies-literature
UnknownExtended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Not available
S-EPMC6317338 | biostudies-literature
UnknownA phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia.
Not available
S-EPMC4732760 | biostudies-literature
Sort   by:  
 Page size